Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
IPO
Biotech
Iambic aims for $135M IPO to push cancer drugs through clinic
Iambic Therapeutics aims to raise $135 million in net proceeds from an IPO as it looks to fund the clinical development of its lead cancer drug.
James Waldron
Oct 8, 2026 8:45am
TRex eyes $111M IPO, as Retension and Lycia also look to Nasdaq
Oct 6, 2026 3:47am
ADARx scores upsized $446M IPO, while City maps out Nasdaq plans
Sep 25, 2026 2:46am
Iambic maintains momentum from Big Pharma collabs with IPO plans
Sep 22, 2026 3:14am
Retension, Lilly-backed TRex both plan to join IPO stampede
Sep 21, 2026 4:29am
Electra charges up with $350M from upsized IPO
Sep 18, 2026 2:58am
